TMT‐Based Quantitative Proteomic Profiling of Human Esophageal Cancer Cells Reveals the Potential Mechanism and Potential Therapeutic Targets Associated With Radioresistance
Aidi Gao,Chao He,Hengrui Chen,Qianlin Liu,Yin Chen,Jianying Sun,Chuanfeng Wu,Ya Pan,Sonia Rocha,Mu Wang,Jundong Zhou
DOI: https://doi.org/10.1002/prca.202400010
2024-10-08
PROTEOMICS - CLINICAL APPLICATIONS
Abstract:Purpose The recurrence of esophageal squamous cell carcinoma (ESCC) in radiation therapy treatment presents a complex challenge due to its resistance to radiation. However, the mechanism underlying the development of radioresistance in ESCC remains unclear. In this study, we aim to uncover the mechanisms underlying radioresistance in ESCC cells and identify potential targets for radiosensitization. Methods We established two radio‐resistant cell lines, TE‐1R and KYSE‐150R, from the parental ESCC cell lines TE‐1 and KYSE‐150 through fractionated irradiation. A TMT‐based quantitative proteomic profiling approach was applied to identify changes in protein expression patterns. Cell Counting Kit‐8, colony formation, γH2AX foci immunofluorescence and comet assays were utilized to validate our findings. The downstream effectors of the DNA repair pathway were confirmed using an HR/NHEJ reporter assay and Western blot analysis. Furthermore, we evaluated the expression of potential targets in ESCC tissues through immunohistochemistry combined with mass spectrometry. Results Over 2,000 proteins were quantitatively identified in the ESCC cell lysates. A comparison with radio‐sensitive cells revealed 61 up‐regulated and 14 down‐regulated proteins in the radio‐resistant cells. Additionally, radiation treatment induced 24 up‐regulated and 12 down‐regulated proteins in the radio‐sensitive ESCC cells. Among the differentially expressed proteins, S100 calcium binding protein A6 (S100A6), glutamine gamma‐glutamyltransferase 2 (TGM2), glycogen phosphorylase, brain form (PYGB), and Thymosin Beta 10 (TMSB10) were selected for further validation studies as they were found to be over‐expressed in the accumulated radio‐resistant ESCC cells and radio‐resistant cells. Importantly, high S100A6 expression showed a positive correlation with cancer recurrence in ESCC patients. Our results suggest that several key proteins, including S100A6, TGM2, and PYGB, play a role in the development of radioresistance in ESCC. Conclusions Our results revealed that several proteins including Protein S100‐A6 (S100A6), Protein‐glutamine gamma‐glutamyltransferase 2 (TGM2), Glycogen phosphorylase, brain form (PYGB) were involved in radio‐resistance development. These proteins could potentially serve as biomarkers for ESCC radio‐resistance and as therapeutic targets to treat radio‐resistant ESCC cells.
biochemical research methods